Renovorx Inc Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RNXT SEC filings page.
Renovorx Inc (RNXT) reported $2.0M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
RenovoRx operates as a development-stage business whose financing, rather than operating sales, funds continued investment.
In FY2025, research and development spending reached$6.3M while revenue was only$1.1M , so the company’s cost base is still built for development activity rather than current sales volume. Operating cash flow of-$11.0M was nearly matched by$10.8M of financing inflow, linking ongoing operations directly to external capital.
Revenue expanded from
The balance sheet is less debt-heavy than the cash-flow pattern might suggest: debt-to-equity fell to 0.5x from 0.8x, while the latest reported liquidity comparison was 7.7 months of annual operating outflow. With capital expenditures of only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Renovorx Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Renovorx Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Not available for Renovorx Inc, and counted as zero in the overall score.
Renovorx Inc has a moderate D/E ratio of 0.49. This balance of debt and equity financing earns a leverage score of 60/100.
With a current ratio of 4.02, Renovorx Inc holds $4.02 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 86/100.
Renovorx Inc's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Renovorx Inc posts a -206.0% return on equity (ROE), meaning it loses $206 for every $100 of shareholders' equity. This results in a returns score of 2/100. This is down from -196.8% the prior year.
Renovorx Inc scores 6.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($95.2M) relative to total liabilities ($2.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Renovorx Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
Renovorx Inc reported a net loss of $11.2M while operations used $11.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Renovorx Inc generated $909K in revenue in Q2 2026. This represents an increase of 115.4% from the same quarter a year earlier. Against the prior quarter it is up 61.5%.
Renovorx Inc reported -$2.9M in net income in Q2 2026. This represents a decrease of 0.6% from the same quarter a year earlier. Against the prior quarter it is up 17.3%.
Renovorx Inc earned -$0.06 per diluted share (EPS) in Q2 2026. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 33.3%.
Not reported for Q2 2026.
Cash & Balance Sheet
Renovorx Inc recorded an outflow of $2.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 27.6% from the same quarter a year earlier. Against the prior quarter it is up 20.8%.
Renovorx Inc held $9.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Renovorx Inc's gross margin was 84.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 20.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Renovorx Inc's ROE was -32.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Renovorx Inc invested $1.2M in research and development in Q2 2026. This represents a decrease of 15.8% from the same quarter a year earlier. Against the prior quarter it is down 2.3%.
Renovorx Inc invested $71K in capex in Q2 2026, funding long-term assets and infrastructure.
Not reported for Q2 2026.
RNXT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $909K+115.4% | $563K+185.8% | $238K | $266K | $422K | $197K | N/A | N/A |
| Cost of Revenue | $143K-5.9% | $84K-10.6% | $28K | $53K | $152K | $94K | N/A | N/A |
| Gross Profit | $766K+183.7% | $479K+365.0% | $210K | $213K | $270K | $103K | N/A | N/A |
| R&D Expenses | $1.2M-15.8% | $1.2M-25.2% | $1.5M | $1.7M+2.1% | $1.4M-7.5% | $1.6M+30.6% | N/A | $1.6M+1.3% |
| SG&A Expenses | $2.9M+91.5% | $2.7M+73.1% | $2.2M | $1.7M+46.7% | $1.5M+2.0% | $1.6M+28.9% | N/A | $1.2M-13.0% |
| Operating Income | -$3.3M-25.1% | -$3.5M-11.5% | -$3.5M | -$3.2M-13.2% | -$2.7M+11.7% | -$3.1M-25.6% | N/A | -$2.8M+5.2% |
| EBITDA | N/A | -$3.5M-11.5% | -$3.5M | -$2.2M | -$1.7M | -$3.1M | N/A | N/A |
| Income Tax | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | -$2.9M-0.6% | -$3.5M-45.5% | -$2.9M | -$2.9M-17.8% | -$2.9M-21.2% | -$2.4M-124.9% | N/A | -$2.5M-73.9% |
| EPS (Diluted) | -$0.06+25.0% | -$0.09-12.5% | -$0.08+33.3% | -$0.08+20.0% | -$0.08 | -$0.08 | -$0.12 | -$0.10 |
Not reported in any period shown, so not listed: Interest Expense, EPS (Basic), Diluted Shares (Avg).
RNXT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.5M-15.9% | $14.0M-12.8% | $8.1M-0.3% | $11.2M+11.7% | $13.6M+13.7% | $16.0M+234.5% | $8.1M+453.8% | $10.0M+185.1% |
| Current Assets | $10.8M-19.3% | $13.7M-12.9% | $7.9M+0.8% | $11.0M | $13.4M | $15.7M | $7.8M+434.0% | N/A |
| Cash & Equivalents | $9.5M-23.0% | $12.4M-15.2% | $7.0M-1.8% | $10.0M+5.0% | $12.3M+4.9% | $14.6M+232.2% | $7.2M+509.9% | $9.6M+196.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $383K | $379K | $189K | $272K | N/A | N/A | $0 | N/A |
| Accounts Receivable | $480K+32.2% | $280K+15.7% | $139K+223.3% | $169K | $363K | $242K | $43K | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.5M-17.0% | $2.7M-5.5% | $2.7M-26.6% | $3.1M+5.7% | $3.0M+9.9% | $2.9M-5.4% | $3.6M+337.3% | $3.0M-15.7% |
| Current Liabilities | $1.9M+21.1% | $1.9M+10.6% | $2.0M+2.8% | $1.9M+6.3% | $1.6M+18.7% | $1.7M+58.8% | $1.9M+62.5% | $1.8M+10.4% |
| Total Equity | $9.0M-15.6% | $11.3M-14.4% | $5.4M+21.1% | $8.1M+14.2% | $10.6M+14.8% | $13.2M+644.6% | $4.5M+49.3% | $7.1M+117750.0% |
| Retained Earnings | -$67.8M-22.1% | -$64.9M-23.3% | -$61.4M-22.2% | -$58.4M-23.5% | -$55.5M-23.8% | -$52.6M-23.9% | -$50.2M-21.3% | -$47.3M-24.0% |
Not reported in any period shown, so not listed: Goodwill, Non-Current Liabilities, Long-Term Debt.
RNXT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-24.5% | -$3.7M-9.7% | -$3.0M-24.3% | -$2.3M-3.5% | -$2.3M-0.2% | -$3.4M-53.4% | -$2.4M-18.4% | -$2.2M+19.6% |
| Depreciation & Amortization | N/A | $1K0.0% | $0 | $1.0M | $1.0M | $1K | N/A | N/A |
| Capital Expenditures | $71K | $0-100.0% | $0 | $0 | $0 | $2K | N/A | N/A |
| Free Cash Flow | -$2.9M-27.6% | -$3.7M-9.6% | -$3.0M | -$2.3M | -$2.3M | -$3.4M | N/A | N/A |
| Investing Cash Flow | -$71K | $0+100.0% | $0 | $0 | $0 | -$2K | N/A | N/A |
| Financing Cash Flow | $55K+61.8% | $9.0M-16.3% | $0-100.0% | $0-100.0% | $34K-99.6% | $10.8M+99.5% | $33K | $15K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
RNXT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.3%+20.3pp | 85.1%+32.8pp | 88.2% | 80.1% | 64.0% | 52.3% | N/A | N/A |
| Operating Margin | -368.4% | -616.2% | -1479.8% | -1203.0% | -634.6% | -1578.7% | N/A | N/A |
| Net Margin | -320.2% | -625.4% | -1235.7% | -1094.7% | -686.0% | -1228.4% | N/A | N/A |
| Return on Equity | -32.4%-5.2pp | -31.3%-12.9pp | -54.2% | -36.0%-1.1pp | -27.2%-1.4pp | -18.4%+42.5pp | N/A | -34.9%+23648.4pp |
| Return on Assets | -25.4%-4.1pp | -25.2%-10.1pp | -36.3% | -26.0%-1.4pp | -21.2%-1.3pp | -15.1%+7.4pp | N/A | -24.6%+15.8pp |
| Current Ratio | 5.74-2.9x | 7.15-1.9x | 4.02-0.1x | 5.83 | 8.61 | 9.07 | 4.10+2.9x | N/A |
| Debt-to-Equity | 0.280.0x | 0.240.0x | 0.49-0.3x | 0.390.0x | 0.280.0x | 0.22-1.5x | 0.81 | 0.42-585.1x |
| FCF Margin | -323.2% | -658.8% | -1268.9% | -853.4% | -545.5% | -1717.3% | N/A | N/A |
Not reported in any period shown, so not listed: Asset Turnover.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Renovorx Inc RNXT | FY2025 | $1.1M | -$11.2M | N/A | $95.2M | 25/100 |
| Plus Therapeutics Inc PSTV | FY2025 | $5.2M | -$22.4M | N/A | $26.6M | 32/100 |
| Bioatla, Inc. BCAB | FY2025 | N/A | $59.6M | N/A | $2.9M | — |
| Tempest Therapeutics Inc TPST | FY2025 | N/A | -$26.3M | N/A | $17.4M | — |
| Telomir Pharms TELO | FY2025 | N/A | -$10.4M | N/A | $75.7M | — |
| Renovaro RENB | FY2025 | N/A | N/A | N/A | $32.9M | — |
Where Renovorx Inc Ranks
Frequently Asked Questions
What is Renovorx Inc's annual revenue?
Renovorx Inc (RNXT) reported $1.1M in total revenue for fiscal year 2025. This represents a 2511.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Renovorx Inc's revenue growing?
Renovorx Inc (RNXT) revenue grew by 2511.6% year-over-year, from $43K to $1.1M in fiscal year 2025.
Is Renovorx Inc profitable?
No, Renovorx Inc (RNXT) reported a net income of -$11.2M in fiscal year 2025.
What is Renovorx Inc's EBITDA?
Renovorx Inc (RNXT) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Renovorx Inc's gross margin?
Renovorx Inc (RNXT) had a gross margin of 70.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Renovorx Inc's return on equity (ROE)?
Renovorx Inc (RNXT) has a return on equity of -206.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Renovorx Inc's free cash flow?
Renovorx Inc (RNXT) recorded an outflow of $11.0M in free cash flow during fiscal year 2025. This represents a -20.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Renovorx Inc's operating cash flow?
Renovorx Inc (RNXT) recorded an outflow of $11.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Renovorx Inc's total assets?
Renovorx Inc (RNXT) had $8.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Renovorx Inc's capital expenditures?
Renovorx Inc (RNXT) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Renovorx Inc spend on research and development?
Renovorx Inc (RNXT) invested $6.3M in research and development during fiscal year 2025.
What is Renovorx Inc's current ratio?
Renovorx Inc (RNXT) had a current ratio of 4.02 as of fiscal year 2025, which is generally considered healthy.
What is Renovorx Inc's debt-to-equity ratio?
Renovorx Inc (RNXT) had a debt-to-equity ratio of 0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Renovorx Inc's return on assets (ROA)?
Renovorx Inc (RNXT) had a return on assets of -138.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Renovorx Inc's P/E ratio?
Renovorx Inc (RNXT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $95.2M as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Renovorx Inc's price-to-sales ratio?
Renovorx Inc (RNXT) trades at 48.2x sales, its market capitalization divided by revenue of $2.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $95.2M as of Sep 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Renovorx Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Renovorx Inc (RNXT) held $7.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.0M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Renovorx Inc's Altman Z-Score?
Renovorx Inc (RNXT) has an Altman Z-Score of 6.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Renovorx Inc's Piotroski F-Score?
Renovorx Inc (RNXT) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Renovorx Inc's earnings high quality?
Renovorx Inc (RNXT) reported a net loss of $11.2M while operations used $11.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Renovorx Inc?
Renovorx Inc (RNXT) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.